Shandong Buchang Pharmaceuticals (603858.SH): Qianlie Shutong Capsules have obtained marketing authorization approval in Indonesia.

Shandong Buchang Pharmaceuticals (603858.SH) announced that recently, the company received marketing authorization approval issued by the National Agency of Drug and Food Control of the Republic of Indonesia, and Qianlie Shutong Capsules, a product of the company's wholly-owned subsidiary Baoding Tianhao Pharmaceutical Co., Ltd., were approved for traditional medicine registration. Qianlie Shutong Capsules are an exclusive product of the company and have been included in the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance" (2025 edition). Its indications are: clearing heat and promoting diuresis, transforming blood stasis and dispersing masses. It is used for chronic prostatitis and benign prostatic hyperplasia belonging to the syndrome of damp-heat and blood stasis obstruction, with symptoms including: frequent urination, urgency of urination, dribbling urination, distending or pain in the perineum, lower abdomen, or lumbosacral region, and dampness of the scrotum, etc.